The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Participant must be aged greater than or equal (≥)18 years at the time of signing the informed consent
validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline
Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening and Baseline
Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
Active dermatologic conditions that may confound the diagnosis of AtD or would interfere with assessment of treatment, such as but not limited to scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic or irritant contact dermatitis
Presence or family history (first degree) of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline (including herpes zoster) as judged by the investigator